Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Omar Al-Attas, Nasser Al-Daghri, Majed Alokail, SherifAbd-Alrahman, Benjamin Vinodson and Shaun Sabico
Posters-Accepted Abstracts: J Clin Trials
Thiamine deficiency has been documented to be prevalent in patients with diabetes mellitus, and correction of thiamine
deficiency in this population may provide beneficial effects in the improvement of several cardiometabolic parameters,
including prevention of impending complications secondary to chronic hyperglycemia. In this interventional study, we aim
to determine whether thiamine supplementation is associated with cardiometabolic improvements in patients with diabetes
mellitus type 2 (DMT2). A total of 86 subjects (60 DMT2 and 26 age- and BMI-matched controls) were included and were given
thiamine supplements (100 mg/day) for 6 months. Anthropometrics and metabolic profiles were measured routinely. Serum
thiamine and its derivatives were measured using high performance liquid chromatography. In all groups there was a significant
decrease in total cholesterol after 3 months (p=0.03) as well as HDL-cholesterol after 6 month thiamine supplementation
(p=0.009). Significant improvements were also observed in the mean serum levels of creatinine (p=0.001), as well as thiamine
and its derivatives in both serum and urinary thiamine levels across follow-up visits (p-values 0.002 and <0.001, respectively).
In the DMT2 group, improvements were observed in lipid profile [mean serum LDL- and total cholesterol with p-values 0.008
and 0.006, respectively], serum thiamine (p<0.001), TMP (p<0.001), TDP (p<0.001), urinary thiamine (p<0.001) and serum
creatinine (p<0.001). Thiamine supplementation is a promising adjuvant therapy for patients with DMT2. Longer clinical trials
are needed to determine its protective effect in DMT2 complications.